Key Points
- Insider sale: Evommune insider Gregory Moss sold 14,223 shares at an average price of $22.83, totaling $324,711.09. After the sale, he still held 60,835 shares, a reduction of about 18.95% in his position.
- Stock moved lower: Shares of Evommune were down 5.1% and opened at $22.04, with the company valued at about $793.7 million. The stock remains well below its 52-week high of $33.20 but above its 52-week low of $13.89.
- Earnings and analyst view: Evommune reported a quarterly loss of $0.64 per share, beating expectations of a $0.83 loss. Analysts currently have a consensus Buy rating with an average price target of $49.25.
Evommune, Inc. (NYSE:EVMN - Get Free Report) insider Gregory Moss sold 14,223 shares of the business's stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $22.83, for a total transaction of $324,711.09. Following the completion of the transaction, the insider owned 60,835 shares in the company, valued at $1,388,863.05. This trade represents a 18.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Evommune Stock Down 5.1%
Shares of NYSE EVMN opened at $22.04 on Tuesday. The firm has a market cap of $793.70 million and a P/E ratio of -2.32. Evommune, Inc. has a 52-week low of $13.89 and a 52-week high of $33.20. The stock has a 50 day moving average price of $24.12.
Evommune (NYSE:EVMN - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.83) by $0.19. On average, sell-side analysts expect that Evommune, Inc. will post -2.83 earnings per share for the current year.
Institutional Trading of Evommune
Institutional investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. bought a new stake in shares of Evommune in the 4th quarter worth $34,000. Strs Ohio bought a new stake in shares of Evommune in the 1st quarter worth $41,000. The Manufacturers Life Insurance Company bought a new stake in shares of Evommune in the 4th quarter worth $179,000. XTX Topco Ltd bought a new stake in shares of Evommune in the 4th quarter worth $321,000. Finally, Oxford Asset Management LLP bought a new stake in shares of Evommune in the 4th quarter worth $335,000.
Analyst Ratings Changes
A number of research firms recently issued reports on EVMN. Royal Bank Of Canada reiterated an "outperform" rating and set a $48.00 target price on shares of Evommune in a research report on Friday, April 10th. Weiss Ratings began coverage on shares of Evommune in a research report on Tuesday, February 3rd. They set a "sell (e)" rating on the stock. Wall Street Zen upgraded shares of Evommune from a "sell" rating to a "hold" rating in a research report on Sunday, May 10th. Morgan Stanley boosted their target price on shares of Evommune from $54.00 to $55.00 and gave the company an "overweight" rating in a research report on Monday, May 11th. Finally, Clear Str upgraded shares of Evommune to a "strong-buy" rating in a research report on Tuesday, March 17th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Evommune presently has a consensus rating of "Buy" and a consensus price target of $49.25.
Get Our Latest Stock Report on Evommune
Evommune Company Profile
(
Get Free Report)
Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients' quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
